Literature DB >> 2424367

Effects of 2,2'-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice.

W G Liu, Z J Chen, J Z Song, Z X Ma.   

Abstract

The effects of 2,2'-O-cyclocytidine (CC) and acyclovir (ACV) on latent herpes simplex virus (HSV) in trigeminal ganglia were studied in an in vitro model using reactivation of HSV type 1 (HSV-1) as a model. It was shown that both CC (10 micrograms/ml) and ACV (2.5 micrograms/ml) significantly inhibited the reactivation of the latent HSV-1 in infected ganglia. The effect of CC (25 micrograms/ml), which was as good as that of ACV (10 micrograms/ml), did not last as long as that of ACV after removal of the drugs. The latent state of HSV-1 in vitro was dependent on the continuous presence of either drug. Even though the latent HSV-1 could not be eliminated completely from the trigeminal ganglia by discontinuous administration of either drug, its titers were markedly reduced. The combination of CC and ACV had a synergistic effect on preventing the reactivation of the latent HSV-1 in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424367      PMCID: PMC176390          DOI: 10.1128/AAC.29.2.278

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro system for studying the efficacy of antiviral agents in preventing the reactivation of latent herpes simplex virus.

Authors:  C Wohlenberg; H Openshaw; A L Notkins
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

2.  Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice.

Authors:  R J Klein; E DeStefano; A E Friedman-Kien; E Brady
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

3.  Ganglionic herpes simplex and systemic acyclovir.

Authors:  D Pavan-Langston; N H Park; M Hettinger
Journal:  Arch Ophthalmol       Date:  1981-08

4.  Oral antiviral drugs in experimental herpes simplex keratitis.

Authors:  H E Kaufman; E D Varnell; Y M Centifanto-Fitzgerald; E De Clercq; G E Kissling
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

5.  Effect of acyclovir, bromovinyldeoxyuridine, vidarabine, and L-lysine on latent ganglionic herpes simplex virus in vitro.

Authors:  N H Park; D Pavan-Langston; E Declercq
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

Review 6.  Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds.

Authors:  R J Klein
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

7.  Combined interaction of antiherpes substances and interferon beta on the multiplication of herpes simplex virus.

Authors:  C Janz; R Wigand
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

8.  Effect of acyclovir on acute and latent herpes simplex virus infections in the rabbit.

Authors:  M D Trousdale; E C Dunkel; A B Nesburn
Journal:  Invest Ophthalmol Vis Sci       Date:  1980-11       Impact factor: 4.799

9.  Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment of maintenance of latent herpes simplex virus infection in mice.

Authors:  H J Field; E De Clercq
Journal:  J Gen Virol       Date:  1981-10       Impact factor: 3.891

  9 in total
  2 in total

Review 1.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

2.  Inhibition of herpes simplex virus-1 infection by MBZM-N-IBT: in silico and in vitro studies.

Authors:  Abhishek Kumar; Saikat De; Alok Kumar Moharana; Tapas Kumar Nayak; Tanuja Saswat; Ankita Datey; Prabhudutta Mamidi; Priyadarsee Mishra; Bharat Bhusan Subudhi; Soma Chattopadhyay
Journal:  Virol J       Date:  2021-05-26       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.